Efficacy of Hylenex in the Treatment of Pain Among Hospice Patients
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The overall aim of this study is to find out whether Hylenex recombinant (for short, Hylenex)
in subcutaneous (SC) injection improves the speed and effectiveness of SC opioids in hospice
patients. Specifically, this study proposes to compare the level of self-reported pain in
hospice patients started on SC infusions of morphine and hydromorphone (Dilaudid) over the
initial 8 hours of opioid infusion with and without the preceded co-injection of Hylenex.
Hospice patients include both home-bound patients as well as those under intensive care in
hospice houses.